Lifevantage Corp (LFVN) — SEC Financial Statements & Analysis

Lifevantage Corp (LFVN) is a pharmaceutical preparations company. Lifevantage Corp trades on Nasdaq as: LFVN. Lifevantage Corp (LFVN)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-08-27. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Lifevantage Corp carries a market cap of $77.59M, a P/E ratio of 15.30x, a P/B ratio of 2.31x, a P/S ratio of 0.42x, an enterprise value of $62.67M, and an EV/EBITDA multiple of 7.06x. On profitability, it posts a gross margin of 77.56%, an operating margin of 3.34%, a net margin of 2.78%, a Return on Equity (ROE) of 14.87%, a Return on Assets (ROA) of 7.57%, and a Return on Invested Capital (ROIC) of 24.68%. Per share, it reports EPS of $0.40, diluted EPS of $0.40, free cash flow per share of $0.53, and a dividend per share of $0.19. Over the trailing year, it posted revenue growth of -20.10% year-over-year, net income growth of -48.27% year-over-year, and EPS growth of -49.44% year-over-year. On the balance sheet, it maintains a current ratio of 1.89x, a quick ratio of 0.95x, working capital of $18.07M, a debt-to-equity ratio of 0.85x, a debt ratio of 0.46, an interest coverage ratio of 37.20x, free cash flow of $6.67M (TTM), and net debt of $-14.92M. Figures sourced from SEC EDGAR.

Market Cap

$77.59M

P/E TTM

15.30x

EPS TTM

$0.40

P/B TTM

2.31x

ROE TTM

14.87%

ROA TTM

7.57%

Debt To Equity

0.85x

Free Cash Flow TTM

$6.67M

Net Revenue TTM Growth 1Y

-20.10%

Data as of 2026-06-30 · Source: SEC EDGAR